var path='https://www.tickertech.net'; function heading(heading) { document.write('
'+heading+' |
'+ ''+ ' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('4/30 - 12:22 PM \; \; | \n'); } if (allow) { document.write('Tuesday\'s ETF Movers: IHE, URA [VIDEO] | \n'); } if (allow) { document.write('
4/30 - 7:05 AM \; \; | \n'); } if (allow) { document.write('Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy\; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040\; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy | \n'); } if (allow) { document.write('
4/30 - 7:01 AM \; \; | \n'); } if (allow) { document.write('Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets | \n'); } if (allow) { document.write('
4/16 - 8:06 AM \; \; | \n'); } if (allow) { document.write('HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 | \n'); } if (allow) { document.write('
4/11 - 8:06 AM \; \; | \n'); } if (allow) { document.write('HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST | \n'); } if (allow) { document.write('
4/3 - 8:06 AM \; \; | \n'); } if (allow) { document.write('HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME | \n'); } if (allow) { document.write('
3/26 - 8:06 AM \; \; | \n'); } if (allow) { document.write('HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE | \n'); } if (allow) { document.write('
2/28 - 8:06 AM \; \; | \n'); } if (allow) { document.write('HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES | \n'); } if (allow) { document.write('
2/22 - 7:30 AM \; \; | \n'); } if (allow) { document.write('Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | \n'); } if (allow) { document.write('
2/21 - 8:06 AM \; \; | \n'); } if (allow) { document.write('U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES\' APPLICATION FOR WAKIX®\; (PITOLISANT) IN PEDIATRIC NARCOLEPSY | \n'); } if (allow) { document.write('
2/20 - 8:06 AM \; \; | \n'); } if (allow) { document.write('HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME | \n'); } if (allow) { document.write('
2/8 - 8:06 AM \; \; | \n'); } if (allow) { document.write('HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 22, 2024 | \n'); } if (allow) { document.write('
1/8 - 8:06 AM \; \; | \n'); } if (allow) { document.write('HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT\; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE | \n'); } if (allow) { document.write('
1/3 - 8:06 AM \; \; | \n'); } if (allow) { document.write('HARMONY BIOSCIENCES TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE | \n'); } if (allow) { document.write('
\n'); } if (allow) { document.write(' |